Please use this identifier to cite or link to this item: https://observatorio.fm.usp.br/handle/OPI/29420
Full metadata record
DC FieldValueLanguage
dc.contributorSistema FMUSP-HC: Faculdade de Medicina da Universidade de São Paulo (FMUSP) e Hospital das Clínicas da FMUSP
dc.contributor.authorNUNES, Rafaella Almeida Lima
dc.contributor.authorMORALE, Mirian Galliote
dc.contributor.authorSILVA, Gabriela Avila Fernandes
dc.contributor.authorVILLA, Luisa Lina
dc.contributor.authorTERMINI, Lara
dc.date.accessioned2018-11-21T17:00:49Z
dc.date.available2018-11-21T17:00:49Z
dc.date.issued2018
dc.identifier.citationCLINICS, v.73, suppl.1, article ID UNSP e549s, 7p, 2018
dc.identifier.issn1807-5932
dc.identifier.urihttps://observatorio.fm.usp.br/handle/OPI/29420
dc.description.abstractMost human papillomavirus infections are readily cleared by the host immune response. However, in some individuals, human papillomavirus can establish a persistent infection. The persistence of high-risk human papillomavirus infection is the major risk factor for cervical cancer development. These viruses have developed mechanisms to evade the host immune system, which is an important step in persistence and, ultimately, in tumor development. Several cell types, receptors, transcription factors and inflammatory mediators involved in the antiviral immune response are viral targets and contribute to tumorigenesis. These targets include antigen-presenting cells, macrophages, natural killer cells, Toll-like receptors, nuclear factor kappa B and several cytokines and chemokines, such as interleukins, interferon and tumor necrosis factor. In the present review, we address both the main innate immune response mechanisms involved in HPV infection clearance and the viral strategies that promote viral persistence and may contribute to cancer development. Finally, we discuss the possibility of exploiting this knowledge to develop effective therapeutic strategies.
dc.language.isoeng
dc.publisherHOSPITAL CLINICAS, UNIV SAO PAULO
dc.relation.ispartofClinics
dc.rightsopenAccess
dc.subjectInnate Immune System
dc.subjectHuman Papillomavirus
dc.subjectCervical Cancer
dc.subject.othertumor-associated macrophages
dc.subject.othersquamous-cell carcinoma
dc.subject.otherhuman-papillomavirus infection
dc.subject.othercervical intraepithelial neoplasia
dc.subject.otherregulatory t-cells
dc.subject.otherclinicopathological correlation
dc.subject.otherhuman keratinocytes
dc.subject.othernecrosis-factor
dc.subject.othermyeloid cells
dc.subject.othercancer
dc.titleInnate immunity and HPV: friends or foes
dc.typearticle
dc.rights.holderCopyright HOSPITAL CLINICAS, UNIV SAO PAULO
dc.identifier.doi10.6061/clinics/2018/e549s
dc.identifier.pmid30328949
dc.subject.wosMedicine, General & Internal
dc.type.categoryreview
dc.type.versionpublishedVersion
hcfmusp.description.articlenumberUNSP e549s
hcfmusp.description.issuesuppl 1
hcfmusp.description.volume73
hcfmusp.origemWOS
hcfmusp.origem.idWOS:000684065500028
hcfmusp.origem.id2-s2.0-85055076705
hcfmusp.origem.idSCIELO:S1807-59322018000200328
hcfmusp.publisher.citySAO PAULO
hcfmusp.publisher.countryBRAZIL
hcfmusp.relation.referenceBeglin M, 2009, J INTERF CYTOK RES, V29, P629, DOI 10.1089/jir.2009.0075
hcfmusp.relation.referenceBoccardo E, 2004, VIROLOGY, V328, P233, DOI 10.1016/j.virol.2004.07.026
hcfmusp.relation.referenceBolpetti A, 2010, BMC IMMUNOL, V11, DOI 10.1186/1471-2172-11-27
hcfmusp.relation.referenceChen SS, 2013, CANCER EPIDEMIOL, V37, P172, DOI 10.1016/j.canep.2012.10.005
hcfmusp.relation.referenceChong HY, 1999, J CELL PHYSIOL, V178, P275, DOI 10.1002/(SICI)1097-4652(199903)178:3<275::AID-JCP1>3.0.CO;2-Q
hcfmusp.relation.referenceChristensen ND, 2016, MICROB CELL, V3, P476, DOI 10.15698/mic2016.09.530
hcfmusp.relation.referenceCuriel TJ, 2004, NAT MED, V10, P942, DOI 10.1038/nm1093
hcfmusp.relation.referenceD'Souza G, 2007, NEW ENGL J MED, V356, P1944, DOI 10.1056/NEJMoa065497
hcfmusp.relation.referenceDaud II, 2011, INT J CANCER, V128, P879, DOI 10.1002/ijc.25400
hcfmusp.relation.referenceDeNardo DG, 2009, CANCER CELL, V16, P91, DOI 10.1016/j.ccr.2009.06.018
hcfmusp.relation.referenceDoorbar J, 2006, CLIN SCI, V110, P525, DOI 10.1042/CS20050369
hcfmusp.relation.referenceEinstein MH, 2009, HUM VACCINES, V5, P705, DOI 10.4161/hv.5.10.9518
hcfmusp.relation.referenceEruslanov E, 2010, J LEUKOCYTE BIOL, V88, P839, DOI 10.1189/jlb.1209821
hcfmusp.relation.referenceFerlay J., 2013, GLOBOCAN 2012 V1 0 C
hcfmusp.relation.referenceFrazer IH, 2009, VIROLOGY, V384, P410, DOI 10.1016/j.virol.2008.10.004
hcfmusp.relation.referenceFrisch M, 1999, LANCET, V354, P1442, DOI 10.1016/S0140-6736(99)92824-6
hcfmusp.relation.referenceGabrilovich DI, 2012, NAT REV IMMUNOL, V12, P253, DOI 10.1038/nri3175
hcfmusp.relation.referenceGarcia-Iglesias T, 2009, BMC CANCER, V9, DOI 10.1186/1471-2407-9-186
hcfmusp.relation.referenceHaghshenas MR, 2017, INT J PREVENTIVE MED, V8, DOI 10.4103/ijpvm.IJPVM_413_16
hcfmusp.relation.referenceHammes LS, 2007, GYNECOL ONCOL, V105, P157, DOI 10.1016/j.ygyno.2006.11.023
hcfmusp.relation.referenceHasan UA, 2007, J IMMUNOL, V178, P3186, DOI 10.4049/jimmunol.178.5.3186
hcfmusp.relation.referenceHeusinkveld M, 2011, J IMMUNOL, V187, P1157, DOI 10.4049/jimmunol.1100889
hcfmusp.relation.referenceJo EK, 2016, CELL MOL IMMUNOL, V13, P148, DOI 10.1038/cmi.2015.95
hcfmusp.relation.referenceKanodia S, 2007, CURR CANCER DRUG TAR, V7, P79, DOI 10.2174/156800907780006869
hcfmusp.relation.referenceKarim R, 2013, PLOS PATHOG, V9, DOI 10.1371/journal.ppat.1003384
hcfmusp.relation.referenceKarim R, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0017848
hcfmusp.relation.referenceKhunamornpong S, 2009, GYNECOL ONCOL, V112, P241, DOI 10.1016/j.ygyno.2008.09.017
hcfmusp.relation.referenceKim SH, 2009, CARCINOGENESIS, V30, P753, DOI 10.1093/carcin/bgp066
hcfmusp.relation.referenceKuang DM, 2009, J EXP MED, V206, P1327, DOI 10.1084/jem.20082173
hcfmusp.relation.referenceLanier LL, 2008, NAT REV IMMUNOL, V8, P259, DOI 10.1038/nri2276
hcfmusp.relation.referenceLe Bon A, 2002, CURR OPIN IMMUNOL, V14, P432, DOI 10.1016/S0952-7915(02)00354-0
hcfmusp.relation.referenceLepique AP, 2009, CLIN CANCER RES, V15, P4391, DOI 10.1158/1078-0432.CCR-09-0489
hcfmusp.relation.referenceLescaille G, 2013, HUM GENE THER, V24, P533, DOI 10.1089/hum.2012.037
hcfmusp.relation.referenceLiaw KL, 2001, J INFECT DIS, V183, P8, DOI 10.1086/317638
hcfmusp.relation.referenceLo Cigno I, 2015, J VIROL, V89, P7506, DOI 10.1128/JVI.00013-15
hcfmusp.relation.referenceLont AP, 2006, INT J CANCER, V119, P1078, DOI 10.1002/ijc.21961
hcfmusp.relation.referenceLyford-Pike S, 2013, CANCER RES, V73, P1733, DOI 10.1158/0008-5472.CAN-12-2384
hcfmusp.relation.referenceMadsen BS, 2008, INT J CANCER, V122, P2827, DOI 10.1002/ijc.23446
hcfmusp.relation.referenceMartinez FO, 2009, ANNU REV IMMUNOL, V27, P451, DOI 10.1146/annurev.immunol.021908.132532
hcfmusp.relation.referenceMarur S, 2010, LANCET ONCOL, V11, P781, DOI 10.1016/S1470-2045(10)70017-6
hcfmusp.relation.referenceMazibrada J, 2008, GYNECOL ONCOL, V108, P112, DOI 10.1016/j.ygyno.2007.08.095
hcfmusp.relation.referenceMoretta L, 2006, SEMIN IMMUNOL, V18, P151, DOI 10.1016/j.smim.2006.03.002
hcfmusp.relation.referenceMota FF, 1998, TISSUE ANTIGENS, V52, P286, DOI 10.1111/j.1399-0039.1998.tb03046.x
hcfmusp.relation.referenceMunk-Madsen MZ, 2018, HUM VACC IMMUNOTHER, V14, P909, DOI 10.1080/21645515.2017.1407896
hcfmusp.relation.referenceMurai M, 2009, NAT IMMUNOL, V10, P1178, DOI 10.1038/ni.1791
hcfmusp.relation.referenceNguyen CT, 2013, CLIN EXP VACCINE RES, V2, P128, DOI 10.7774/cevr.2013.2.2.128
hcfmusp.relation.referenceNiebler M, 2013, PLOS PATHOG, V9, DOI 10.1371/journal.ppat.1003536
hcfmusp.relation.referenceOliveira LB, 2013, J GEN VIROL, V94, P1858, DOI 10.1099/vir.0.052811-0
hcfmusp.relation.referencePontillo A, 2016, J MED VIROL, V88, P1646, DOI 10.1002/jmv.24514
hcfmusp.relation.referencePsyrri A, 2008, NAT CLIN PRACT ONCOL, V5, P24, DOI 10.1038/ncponc0984
hcfmusp.relation.referenceQuatromoni JG, 2012, J TRANSL MED, V10, DOI 10.1186/1479-5876-10-127
hcfmusp.relation.referenceQuatromoni JG, 2012, AM J TRANSL RES, V4, P376
hcfmusp.relation.referenceRonco LV, 1998, GENE DEV, V12, P2061, DOI 10.1101/gad.12.13.2061
hcfmusp.relation.referenceSajadian A, 2014, ARCH VIROL, V159, P1951, DOI 10.1007/s00705-014-2024-4
hcfmusp.relation.referenceSappayatosok K, 2009, MED ORAL PATOL ORAL, V14, pE319
hcfmusp.relation.referenceScott ME, 2015, INT J CANCER, V136, P2402, DOI 10.1002/ijc.29283
hcfmusp.relation.referenceSenba M, 2012, ONCOL REV, V6, P135, DOI 10.4081/oncol.2012.e17
hcfmusp.relation.referenceShen KY, 2014, HUM VACC IMMUNOTHER, V10, P3241, DOI 10.4161/hv.29275
hcfmusp.relation.referenceSoong RS, 2014, CLIN CANCER RES, V20, P5456, DOI 10.1158/1078-0432.CCR-14-0344
hcfmusp.relation.referenceStanley MA, 2007, BIOCHEM SOC T, V35, P1456, DOI 10.1042/BST0351456
hcfmusp.relation.referenceSunthamala N, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0091473
hcfmusp.relation.referenceTalebi S, 2017, BIOMED PHARMACOTHER, V85, P148, DOI 10.1016/j.biopha.2016.11.115
hcfmusp.relation.referenceTang XQ, 2013, IMMUNOLOGY, V138, P93, DOI 10.1111/imm.12023
hcfmusp.relation.referenceTermini L, 2008, BMC MED GENOMICS, V1, DOI 10.1186/1755-8794-1-29
hcfmusp.relation.referenceTextor S, 2008, INT J CANCER, V123, P2343, DOI 10.1002/ijc.23733
hcfmusp.relation.referenceTextor S, 2011, INT J CANCER, V128, P1104, DOI 10.1002/ijc.25442
hcfmusp.relation.referenceThompson MR, 2011, VIRUSES-BASEL, V3, P920, DOI 10.3390/v3060920
hcfmusp.relation.referenceTummers B, 2015, NAT COMMUN, V6, DOI 10.1038/ncomms7537
hcfmusp.relation.referenceUm SJ, 2002, CANCER LETT, V179, P205, DOI 10.1016/S0304-3835(01)00871-0
hcfmusp.relation.referenceVan den Bergh JMJ, 2014, J CELL MOL MED, V18, P1372, DOI 10.1111/jcmm.12284
hcfmusp.relation.referenceVILLA LL, 1992, MOL CARCINOGEN, V6, P5, DOI 10.1002/mc.2940060103
hcfmusp.relation.referenceWarren CJ, 2017, VIRUSES-BASEL, V9, DOI 10.3390/v9080233
hcfmusp.relation.referenceWei LL, 2009, CANCER RES, V69, P4878, DOI 10.1158/0008-5472.CAN-08-4695
hcfmusp.relation.referenceWOODWORTH CD, 1995, P NATL ACAD SCI USA, V92, P2840, DOI 10.1073/pnas.92.7.2840
hcfmusp.relation.referenceYang W, 2013, IMMUNOLOGY, V139, P513, DOI 10.1111/imm.12101
hcfmusp.relation.referenceYoung JL, 2008, GYNECOL ONCOL, V109, P140, DOI 10.1016/j.ygyno.2008.01.008
hcfmusp.relation.referencezur Hausen H, 2002, NAT REV CANCER, V2, P342, DOI 10.1038/nrc798
hcfmusp.relation.referencezur Hausen H, 2009, VIROLOGY, V384, P260, DOI 10.1016/j.virol.2008.11.046
dc.description.indexMEDLINE
dc.identifier.eissn1980-5322
hcfmusp.citation.scopus13
hcfmusp.scopus.lastupdate2022-05-06
Appears in Collections:

Artigos e Materiais de Revistas Científicas - FM/MDR
Departamento de Radiologia - FM/MDR

Artigos e Materiais de Revistas Científicas - HC/ICESP
Instituto do Câncer do Estado de São Paulo - HC/ICESP

Artigos e Materiais de Revistas Científicas - LIM/24
LIM/24 - Laboratório de Oncologia Experimental

Artigos e Materiais de Revistas Científicas - ODS/03
ODS/03 - Saúde e bem-estar


Files in This Item:
File Description SizeFormat 
art_NUNES_Innate_immunity_and_HPV_friends_or_foes_2018.PDFpublishedVersion (English)471.55 kBAdobe PDFThumbnail
View/Open

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.